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doi:10.1Objective: This study compared graft failure leading to retransplant in infants versus older children at initial
heart transplant.
Methods: Twenty-six retransplant recipients were compared by age at first transplant: infant group (<1 year)
and pediatric group (1 year).
Results: Early retransplant survival was 92%. Retransplant survivals at 1, 3, and 5 years were 83%, 74%, and
67%. There were 15 infant and 11 pediatric patients. First transplant ages were 0.4  0.3 vs. 8.5  5.7 years in
infant and pediatric groups, respectively (P<.01). First graft rejection episodes were more common in pediatric
group (4.8  2.5 vs 3.1  2.1, P ¼ .032), and rejection rate was higher (1.5  1.1 vs 0.4  0.4, P ¼ .0024).
Median first graft survival was longer in infant group (10.7 years vs 3.9 years, P<.001). Recurrent cellular re-
jection was retransplant indication in 40% of infant group versus 91% of pediatric group (P<.05). Cardiac
allograft vasculopathy was more prevalent in infant group (73% vs 20% in pediatric group, P ¼ .032).
Conclusions: Infant heart transplant recipients had longer primary graft survival, fewer cellular rejection
episodes, and higher incidence of cardiac allograft vasculopathy relative to older graft recipients requiring re-
transplant. Advantages in adaptive immunity in infant heart recipients confer improved primary graft survival,
but longer graft life in these patients is limited by cardiac allograft vasculopathy. Older recipient first graft failure
was rejection related, and shorter graft life probably limited development of cardiac allograft vasculopathy.
(J Thorac Cardiovasc Surg 2011;141:223-30)T
XTransplant is effective treatment for infants and childrenwith
end-stage heart failure or congenital heart disease that is not
amenable to repair.1-3 When graft failure occurs in these
patients, retransplant is the only treatment option.4-11
Common causes of graft failure leading to retransplant are
cardiac allograft vasculopathy (CAV), various forms of
rejection, and ‘‘nonspecific’’ graft failure.4-5,7-9,11 Previous
single-center studies have reported excellent outcomes,
with 3-year retransplant survivals equal to primary trans-
plant.5,7,11 These studies, however, are limited by small
patient numbers and short follow-up. LargerUnitedNetwork
for Organ Sharing (UNOS) and Pediatric Heart Transplant
Study (PHTS) registry studies have clearly demonstrated in-
ferior outcomes for repeated transplants relative to primary
transplants in children.4,9 In addition, the 2009
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The Journal of Thoracic and Capediatric registry report now indicates that retransplant is
associated with worse 1- and 5-year outcomes.12-13
Infant heart recipients have superior long-term outcomes
relative to other age groups, with a primary graft half-life of
18 years versus only 11 years for teenagers.12 The infant
survival advantage is presumably due to the plasticity of
their immature immune system, and many centers, includ-
ing ours, use less immunosuppression in infant recipients
to obtain outcomes that exceed those of older children. In
reports derived from registry data from UNOS and PHTS,
CAV was the indication for retransplant for approximately
half of all patients who underwent primary transplant as
children.4,9 Given that 3-year graft survival after
angiographic diagnosis of CAV in children is only 45%,
any angiographic evidence of CAV portends graft
failure.12 Older recipient and donor ages at first transplant
are risk factors for development of CAV, and freedom
from CAV with time is longest in infant recipients.12,14
Although registry data demonstrate superior primary
graft survival for infant heart recipients, this has not been
demonstrated for the subset of patients who have undergone
retransplant. Reports on pediatric heart retransplant also
have not examined the influence of recipient age on the eti-
ology of graft failure leading to retransplant, or determined
whether there is any effect on second graft survival.With the
known outcome differences for primary transplant between
infants and older patients, it is possible that factors leadingrdiovascular Surgery c Volume 141, Number 1 223
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Xto first graft failure and retransplant differ by age at initial
transplant. The aims of this study were (1) to assess early
and midterm outcomes of pediatric heart retransplant at
our center, (2) to determine whether primary and second
graft survivals differ between patients with initial transplant
in infancy and older recipients, and (3) to determinewhether
age at initial transplant affects primary graft failure etiology
and the prevalence of angiographically evident CAVin pedi-
atric patients undergoing retransplant at our center.MATERIALS AND METHODS
Data Collection
The Colorado Multiple Institutional Review Board approved this study.
Awaiver of consent was obtained, and patient data were made anonymous.
All heart transplants performed at our center between 1990 and March
2010 were retrospectively reviewed. Retransplant patients were identified,
and patients were compared by recipient age at initial transplant: infant
group (<1 year) and pediatric group (1 year). The dominant listing diag-
noses for first and second transplants were obtained from the original
UNOS listing entries. At our center, rejection history, serial biopsy, and se-
lective coronary angiographic results are used to establish a dominant list-
ing diagnosis for patients with graft failure related to mixed rejection and
CAV. Classification of graft failure as idiopathic is avoided. Echocardio-
graphic and catheterization data were extracted from the most recent stud-
ies performed before retransplant listing. Variables included ages at first
and second transplants, donor and recipient cytomegalovirus serologic
statuses at each transplant, primary graft rejection episodes, presence and
severity of CAVat retransplant listing, first and second graft survivals, early
and late retransplant mortalities, retransplant ventilator time, and intensive
care unit and hospital stays. Early mortality was considered death before
hospital discharge or within 30 days of retransplant if after discharge.
Immunosuppression and Surveillance
All patients received induction, maintenance immunosuppression, and
graft surveillance according to institutional protocol. Perioperative induc-
tion included steroids, antithymocyte globulin, intravenous immune
globulin, calcineurin-inhibitor (cyclosporine, INN ciclosporin), and azathi-
oprine. Maintenance immunosuppression was steroid free. Infant recipi-
ents who were free of rejection were transitioned to single-drug
maintenance (cyclosporine) after 1 year. Patients who underwent transplant
outside infancy and were free of rejection at 1 year continued dual drug
therapy (cyclosporine and azathioprine). Infant graft surveillance was
primarily noninvasive and consisted of serial clinical assessments and
echocardiograms.15 Initial right heart surveillance catheterization with en-
domyocardial biopsy was performed at 1 year for recipients at least 4 years
old, at 3 months for those aged 4 to 8 years, and at 2 months and 6 months
for patients older than 8 years. All patients underwent endomyocardial
biopsy, hemodynamic assessment, and selective coronary angiography at
1 year after transplant and then at 2-year intervals. Catheterization, biopsy,
and coronary evaluations were done as indicated by conflicting clinical and
echocardiographic findings or for atypical or complex rejection. More
frequent coronary assessment was performed if CAV was diagnosed.224 The Journal of Thoracic and Cardiovascular SurgRetransplant management was protocol based. Perioperative induction
included steroids, azathioprine, calcineurin-inhibitor (cyclosporine or tacro-
limus), intravenous immune globulin, and antithymocyte globulin. Mainte-
nance immunosuppression was dual therapy with calcineurin-inhibitor and
mycophenolate mofetil. Target calcineurin-inhibitor levels were higher
thanwith primary transplants. Immunosuppressionwas adjusted on the basis
of renal function and evidence of hypertension. All retransplant recipients
received total lymphoid irradiation at 1 posttransplant week.
Rejection
A rejection episode was considered an event leading to augmentation of
immunotherapy, as defined by the PHTS.4,16-18 Rejection diagnosis was
based on clinical findings, echocardiography, or endomyocardial biopsy.
Total rejection episodes and rejection rate per graft year were
determined. Rejection was treated with steroids or steroids combined
with antilymphocyte antibody (thymoglobulin or OKT3). Use of adjunct
therapy for resistant rejection depended on the underlying cause of graft
rejection. Treatment of ongoing cellular rejection consisted of total
lymphoid irradiation and additional cytotoxic or antimetabolite therapy.
Resistant antibody-mediated rejection was treated with plasmapheresis
and intravenous immune globulin.
Cardiac Allograft Vasculopathy
Diagnosis of CAV was based on selective coronary angiography and
was classified as none, mild, moderate, or severe according to the Cardiac
Transplant Research Database criteria (methodology adopted by the
PHTS).14,19 All studies were classified by a single independent observer.
Statistical Methods
Continuous variables were compared with independent sample Student
t test. Categoric variables were compared with c2 test of independence and
Fisher’s Exact test. Graft survival was estimated by the Kaplan–Meier
method, and comparisons were with log-rank test. Poisson regression
was used to evaluate the count of rejection episodes. Statistical analysis
was performed with the SAS statistical package version 9.2 (SAS Institute
Inc, Cary, NC).RESULTS
Of 350 pediatric heart transplants, 26 retransplants were
performed in 26 patients. No retransplants were for early
graft failure. One occurred at 1 year, and the remainder
were performed later than 2 years after primary transplant.
Etiologies of graft failure were rejection-related graft
dysfunction (n ¼ 16, 62%), CAV (n ¼ 7, 27%), and right
ventricular failure with severe tricuspid regurgitation
(n ¼ 3, 12%). Five patients with rejection-related failure
also had angiographically evident CAV (2mild, 2 moderate,
1 severe), and 1 patient with right ventricular failure also
had angiographically evident CAV (mild). All 7 patients
with dominant diagnosis of CAV had severe disease. The
mean age at primary transplant was 3.9 5.5 years. Fifteen
patients underwent primary transplant as infants (infant
group), and 11 patients were older than 1 year (pediatric
group). The infant group represented 8.5% of all primary
infant transplants, and the pediatric group represented
7.4% of older primary recipients. Mean ages at primary
transplant were 0.4  0.3 and 8.5  5.7 years for infant
and pediatric groups, respectively (P<.01). Table 1 pres-
ents patient variables at first and second transplants.ery c January 2011
TABLE 1. Patient and group characteristics
Characteristics All patients (n ¼ 26) Infant group (n ¼ 15) Pediatric group (n ¼ 11) P value
Primary transplant
Age at transplant (y, mean  SD) 3.9  5.5 0.4  0.3 8.5  5.7 .0001
Donor age (y, mean  SD) 3.9  11 0.95  0.66 19.1  9.0 <.0001
Listing diagnosis congenital heart disease (no.) 14 (54%) 10 (66.7%) 4 (36.4%) .23
Listing diagnosis cardiomyopathy (no.) 12 (46%) 5 (33.3%) 7 (63.6%) .23
Recipient cytomegalovirus seropositive (no.) 27.3% 38.5% 11.1% .33
Donor cytomegalovirus seropositive (no.) 63.2% 53.9% 83.3% .33
Donor ischemia time (min, mean  SD) 197  65 224  56 155  58 .01
Retransplant
Age at transplant (y, mean  SD) 11.5  4.6 10.6  3.9 12.8  5.3 .25
Listing diagnosis rejection-related graft failure (no.) 16 (61%) 6 (40.0%) 10 (90.9%) .014
Listing diagnosis cardiac allograft vasculopathy (no.) 7 (27%) 6 (40%) 1 (9.1%) .18
Listing diagnosis other* (no.) 3 (11%) 3 (20%) 0 (0%) .24
Donor ischemia (min, mean  SD) 221  63 237  55 195  71 .12
Ventilator time (d, median and range) 1.5 (1–8) 2 (1–3) 1 (1–8) .14
Intensive care unit stay (d, median and range) 5.5 (3–44) 6 (3–9) 5 (3–44) .25
Hospital stay (d, median and range) 7 (5–100) 8 (5–22) 7 (6–100) .25
Early mortality (no.) 2 (8%) 0 (0%) 2 (18%) .17
*Three patients had severe tricuspid regurgitation and right ventricular dysfunction precluding initial or repeated attempts at tricuspid valve repair or replacement.
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XRetransplant Outcomes
Early survival after retransplant was 92%. One patient
died intraoperatively from aortic injury. A second patient
arrested during anesthetic induction and died of severe brain
injury. These deaths were of the first 2 patients in the series,
and there were no early deaths since 1995. There were 7 late
deaths: sudden death with severe CAV at postmortem
(n¼ 4), sepsis (n¼ 2), right ventricular failure with pulmo-
nary hypertension (n¼ 1), and acute rejection (n¼ 1). Two
infant group patients died late (0.7 and 11.9 years), and 5
pediatric group patients died late (0.1, 1.5, 1.6, 4.0, and
9.4 years). No patient underwent a third transplant.
Mean retransplant follow-up for all patients was 4.0 
4.1 years. Median survival after retransplant was 11.9 years.
Estimated retransplant survivals at 1, 3, and 5 years were
83%, 74%, and 67%, respectively (Figure 1). Mean re-FIGURE 1. Kaplan–Meier estimated survival after retransplant for all pa-
tients. Median survival was 11.9 years. Patients at risk are listed above
x-axis.
The Journal of Thoracic and Catransplant follow-ups were 3.3  3.4 years and 5.1  4.9
years for the infant and pediatric groups, respectively. Me-
dian survivals were 11.9 years (95% confidence interval
[CI], 0.71–11.9 years) for the infant group and 4.0 years
(95% CI, 0.041 years to no upper limit) for the pediatric
group (P ¼ .076). Five infant group patients had censored
follow-up less than 1 year, whereas no pediatric group pa-
tients had censored follow-up before 5 years. More late
deaths occurred in the pediatric group, but the number of in-
fant group patients with censored short follow-up precluded
comparison of late survival.Primary Graft Outcomes and Group Comparisons
Median primary graft survival for all patients was 7.2
years. Median primary graft survival for the infant group
was more than double that for the pediatric group (infant
group: 10.7 years; 95% CI, 5.6–11.3 years; vs pediatric
group: 3.9 years; 95% CI, 2.1–5.3 years; P < .001;
Figure 2).
All indices of rejection were greater in the pediatric
group (Figure 3). The mean number of rejection episodes
in the infant group was 3.1  2.1 (range, 0–6), compared
with 4.8  2.5 (range, 2–10) for the pediatric group
(P ¼ .032). Every patient in the pediatric group had 2 or
more rejection episodes. Two infant group patients had no
rejection episodes before retransplant. Because the infant
group graft survival was longer than that in the Pediatric
Group, rejection rate as a function of total graft life was
also assessed. The infant group mean rejection rate (0.4 
0.4 rejection episodes/y) was significantly less than that in
the pediatric group (1.5  1.1 rejection episodes/y,
P ¼ .0024). The pediatric group had more rejectionrdiovascular Surgery c Volume 141, Number 1 225
FIGURE 2. Kaplan–Meier estimated survival of primary transplant graft
by group, with number of patients at risk in each group listed above x-axis
(infant group on top). Median survivals were 11.0 years (range 5.6–11.3
years) for infant group versus 3.9 years (range 2.1–5.3 years) for pediatric
group (P<.001).
TABLE 2. Incidence and classification of cardiac allograft
vasculopathy
Grade Infant group (n ¼ 15) Pediatric group (n ¼ 10*)
None 4 (27%) 8 (80%)
Mild 3 (20%) 0 (0%)
Moderate 2 (13%) 0 (0%)
Severe 6 (40%) 2 (20%)
Any 11 (73%) 2 (20%)y
*Angiogram missing for 1 patient. yP ¼ .032.
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Xepisodes in the first year after primary transplant (infant
group 0.53  0.99 vs pediatric group 1.6  1.9,
P ¼ .0083). According to protocol, patients in the infant
group were managed with lower cyclosporine levels, and
11 of 15 were weaned to single-drug therapy. Recurrent re-
jection was the dominant retransplant listing diagnosis for
10 of 11 pediatric group patients (91%), compared with 6
of 15 infant group patients (40%) (P ¼ .014; Table 1).
Table 2 presents the incidence and severity of primary
graft CAV. Eleven of 15 infant group patients (73%) had
CAV, compared with 2 of 10 patients (20%) in the pediatric
group (P ¼ .032). CAV was the dominant retransplant list-
ing diagnosis for 6 of 15 patients in the infant group (40%),
compared with 1 of 11 pediatric group patients (P ¼ .18).
Putative risk factors for the development of CAV in pediat-
ric recipients that were compared across groups included
older recipient and donor ages,14 rejection episodes withinFIGURE 3. Comparison of rejection episodes and rejection rates by
group.
226 The Journal of Thoracic and Cardiovascular Surg1 year of initial transplant,14 late (>1 year) rejection fre-
quency and severity,20 short donor ischemia time (<2
hours),12 and positive recipient cytomegalovirus serostatus
before first transplant.21 Cytomegalovirus serostatus was
not different between groups (Table 1). The only differences
between groups were older recipient and donor ages for the
pediatric group (Table 1) and the previously delineated
increased indices of rejection observed in the pediatric
group. No putative risk factor for the development of
CAV was increased in the infant group relative to the pedi-
atric group other than the graft time at risk that resulted
from the longer graft survival in the infant group. Notably,
both patients in the infant group with no rejection episodes
had severe CAV.DISCUSSION
The graft half-life after primary heart transplant in pediat-
ric patients currently approaches 14 years.12 Survival is sig-
nificantly better than for adults, but pediatric graft survival
remains limited. Retransplants now comprise 5% of all
pediatric heart transplants performed.12 In centers with large
numbers of transplant recipients, this incidence is probably
higher. In the past 2 years, 7 of 38 pediatric heart transplants
performed at our center (18%) were retransplants. Retrans-
plant is the only viable therapeutic option for graft failure,
and our results substantiate that retransplant in pediatric
patients is reasonable. As demonstrated by others,5,7,11 our
retransplant 1-, 3-, and 5-year outcomes (83%, 74%, and
67%, respectively) are similar to primary transplant
outcomes (85%, 78%, and 75%, respectively, P ¼ .40).
All single-center reports, however, are limited in size and
follow-up.5,7,11 Recent UNOS and International Society
for Heart and Lung Transplantation registry reports clearly
demonstrate worse 5-year outcomes for retransplant than
for primary transplant,4,9,12 and we do not consider
equivalence to primary transplant necessary to justify
retransplant.
Although the mechanism is speculative, the plasticity of
the immature infant immune system probably accounts for
the survival advantage of primary infant transplant recipi-
ents relative to older recipients. Because infants have an
advantage in adaptive immunity, our center andmany others
use less immunosuppression for these recipients, withery c January 2011
Karamichalis et al Cardiothoracic Transplantation
T
Xoutcomes superior to those of older patients. Previous stud-
ies on pediatric retransplant have not assessedwhether age at
first transplant impacts primary graft survival in patients
undergoing retransplant, the etiology of primary graft failure
in this subset, or retransplant graft survival. In our data set,
primary graft survival for infant recipients who underwent
retransplant was substantially better than that for patients
who had undergone primary transplant at an older age.
Because of the known graft survival advantage for infant
recipients,12 the superior primary graft survival in our re-
transplant infant group was not unexpected. The difference
in primary graft survival between age groups (nearly 3-
fold) was, however, more substantial than one would likely
extrapolate from registry data. Whether this survival advan-
tage extends to the second graft remains unanswered. Both
study groups underwent retransplant at similar ages (Table
1), but underlying developmental differences in immunity
and treatment histories may have affected second graft sur-
vival. We observed a trend toward better second graft sur-
vival in the infant group (median, 11.9 years vs 4.0 years
in the pediatric group; P ¼ .076), but our analysis was too
limited by insufficient follow-up in the infant group to
draw a valid conclusion. Longer follow-up may answer
this question, but an analysis of registry data would be
more appropriate.
When we compared our total retransplant experiencewith
those of others, the relative etiologies of graft failure leading
to listing for retransplant differed considerably.4-5,7,9,11 We
observed a lower incidence of CAV as the dominant
diagnosis (27%) and a higher incidence of rejection as the
dominant diagnosis (62%). In registry studies and previous
pediatric single-center series, CAV was the leading etiology
of graft failure, and rejection-related graft failure was less
frequent.4-5,7,9,11-12 Several factors may explain this
disparity. Patient management and recipient age spectrum
may differ at our center. Second, determination of graft
failure etiology when listing a patient for retransplant is
sometimes subjective, and practices vary among centers.
Many centers categorize a significant number of graft
failures as nonspecific or other, and it is possible that many
of these cases would be more definitively classified in our
center.4,7,9,12 Other centers may not distinguish a dominant
etiology in patients with significant rejection history and
concomitant CAV.11We have endeavored to establish a dom-
inant diagnosis for these patients. The choice between rejec-
tion and CAV as the dominant factor in patients with
concomitant etiologies was made on the basis of clinical re-
jection history, serial biopsy findings, and serial coronary as-
sessments. Third, the threshold for listing a patient for
retransplant for CAV probably varies among centers. In our
center, patients with CAVare not listed for retransplant until
there is evidence of rapid progression of CAVor graft failure,
manifesting as hemodynamic compromise, arrhythmia, or
symptoms.A lower threshold at other centerswould increaseThe Journal of Thoracic and Cathe incidence of graft failure from CAV relative to that at our
center. It is well known that coronary arteriography lacks
sensitivity in the detection of CAV until late in the course
of disease20,22; however, the diagnosis of CAV, as with the
other reports, was based on selective coronary arteriography.
All patients in our series underwent angiographic
assessment before listing for retransplant, and it is unlikely
that the overall incidence of angiographically evident CAV
was underestimated. Finally, all patients at our center with
rejection-related etiology had a strong history of recurrent
rejection when listed for retransplant.
We consider themost important findings of our study to be
the differences in rejection and prevalence of angiographi-
cally evident CAV noted between the infant group and the
older children coming to retransplant. International Society
for Heart and Lung Transplantation registry and PHTS
data indicate that the incidence of angiographically
evident CAV is lower in younger recipients at any given
time point through 8 years of follow-up.12,14 In addition,
older recipient and donor ages at transplant are important
risk factors for the development of CAV in pediatric
recipients.14 Thus the high prevalence of CAV observed in
our infant group relative to the older group (73% vs. 20%,
P ¼ 0.032) seems paradoxic. No reported patient CAV risk
factors that we studied were increased in the infant group.
The most likely reason for the age-related difference in
CAV prevalence is therefore the difference in graft survival
between groups (10.7 vs 3.9 years). All studies of CAV indi-
cate that the risk of development of CAVat any age increases
with time. Consequently, graft loss as a result of direct
rejection-mediatedmyocardial injury likely occurred before
angiographically evident CAV had time to develop in the
older patients. Conversely, the longer primary graft life in in-
fant recipients allowed sufficient time for angiographically
evident CAV to develop before retransplant was required
for other reasons. Importantly, severe CAV can occur in
the absence of any history of rejection episodes, as occurred
with 2 of our infant patients.
Because the risk of femoral vessel injury and occlusion is
increased in infants who require lifelong surveillance, rejec-
tion surveillance at our center is primarily noninvasive
during the first year after transplant in infants. Although
first-year surveillance biopsy protocols differed between
the groups, several factors suggest that this difference did
not influence the increased indices of rejection observed
in the pediatric group. First, our surveillance protocol
used for infants was previously validated against endomyo-
cardial biopsy in this age range.15 Second, the diagnosis of
rejection at all ages was based on the combination of clini-
cal, echocardiographic, and catheterization studies. Impor-
tantly, only 1 rejection episode in the pediatric group was
diagnosed on the basis of a surveillance biopsy in isolation.
Finally, if rejection episodes were under diagnosed early in
the infant group because of less frequent use of surveillancerdiovascular Surgery c Volume 141, Number 1 227
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Xbiopsies, these missed rejections should have led to inade-
quate immune suppression and clinically apparent rejec-
tions or deaths in the infant group that were not, in fact,
observed. Consequently, we believe that the reported differ-
ences observed in rejection parameters according to age at
primary transplant are real.
The causes of CAVare not well understood, but both im-
mune and nonimmune mechanisms are clearly involved.
Treatment and prevention strategies for CAV in pediatric
patients vary among centers, and although retransplant is
the only option for patients with severe or symptomatic dis-
ease, medical management of CAV is without clear consen-
sus. We have previously described our approach to the
medical management of CAV in children.23
Although CAV was a leading cause of graft failure in the
infant group in this study, the incidence of CAV in our entire
infant primary recipient population was only 12%. In a sep-
arate evaluation of CAV in our entire primary transplant
population, the prevalences of CAV were similar between
infant and pediatric recipients.24 The time to diagnosis of
CAV, however, was significantly longer in infant recipients
than in pediatric recipients (8.0 3.4 years vs 5.4 3 years,
P<.01). The severity of CAVat initial diagnosis was signif-
icantly worse in infant recipients than in pediatric recipi-
ents, and we observed a trend toward shorter time from
diagnosis of CAV to death or retransplant in infant recipi-
ents (0.9  0.9 years vs 2.8  3.4 years, P ¼ .06). Thus
in our experience although CAV develops later in infant re-
cipients, it is more virulent in infant recipients, and more
than 50% of the infants with CAV diagnosed have under-
gone retransplant.
In addition to inherent limitations of retrospective studies,
several factors limit this study.We considered only the subset
of pediatric heart recipients with graft failurewho underwent
retransplant. Comparisons with the total population of pa-
tients undergoing primary transplant would be needed to de-
lineate underlying factors that may have prompted the
increased rejection-related graft failure and shorter primary
graft life in the older retransplant patient group. Likewise,
conclusions regarding the underlying causes of CAV cannot
be made. Although this study represents the largest single-
center experience and longest follow-up for pediatric re-
transplant to date, the patient numbers and relatively short
follow-up limit its power. Finally, some findings in this study
might have differed if patients at our center with graft failure
who died without retransplant or underwent retransplant
elsewhere had been included.
CONCLUSIONS
Our results confirm that heart retransplant is reasonable
treatment for pediatric patients with late graft failure. De-
spite less aggressive immunosuppression, infant heart trans-
plant recipients listed for retransplant had significantly
longer primary graft survival and significantly lower indices228 The Journal of Thoracic and Cardiovascular Surgof clinical rejection before retransplant than did children
who were older at the time of primary transplant. The prev-
alence of primary graft CAVamong infant recipients requir-
ing retransplant was significantly higher than that among
retransplant recipients who were older at primary trans-
plant, despite more rejection in the latter group.
Rejection-mediated injury likely resulted in more rapid
graft failure in the older group before time-related factors
that cause CAV could promote the development of CAV.
Despite the primary graft survival advantage enjoyed by
infant heart recipients, CAV is a major cause of graft loss
in this age group.References
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XDiscussion
Dr Jonathan Chen (New York, NY). I would like to congratu-
late Dr Karamichalis and colleagues from the Denver Children’s
Hospital on an impressive series from one of the leading centers
for pediatric heart transplantation in North America.
While survival following transplantation continues to improve,
regrettably a sizable minority of these recipients will require re-
transplantation and, in this way, transplantation is for many chil-
dren a palliative procedure that merely postpones an inevitable
graft replacement anywhere from several years to several decades
following the primary operation.
Our findings at Columbia have mirrored those of Denver, sug-
gesting that the survival outcomes following retransplantation
are now comparable to primary transplantation in well-selected
candidates. The report today seeks to further characterize this sub-
cohort of retransplant candidates with a particular interest on the
age at their primary procedure.
Having had, thank you, the benefit to review your data prior to
this presentation, I have 4 questions for the authors.
The first is: Were there any children with graft failure who were
not deemed retransplant candidates during your study period and
thus did not make it into this study?
Dr Karamichalis.We had patients whowere listed on the wait-
ing list for retransplantation. We had 10 patients who were listed
for retransplantation: 5 of them died on the transplant list, 2 of
them were transferred to another facility, and 3 of them were re-
moved from the list because their condition improved.
Dr Chen. Second, how was the decision made to divide these
patients into groups that were greater than and less than 1 year
of age? Inferences from ABO-incompatible strategies would sug-
gest that the time of so-called immunologic privilege can extend as
far as 14 months or longer.
Dr Karamichalis. Because of the known immaturity of the in-
fant immune system, we felt that the infant recipient population
would have an advantage over anybody over 1-year-old, so we di-
vided the groups into less than 1 year or over 1 year. The ISHLT
database registry divides these patients into more than 2 sub-The Journal of Thoracic and Cagroups; however, because of our small group, we decided to
draw the line between infants and older than 1.
DrChen.Third, I’m somewhat perplexed still at the finding that
there is more transplant coronary disease but fewer incidences of
rejection in your infant subcohort. And I wonder whether some
of this could be due to the differences in surveillance that you de-
scribewith respect to your age-based protocols that dictate the tim-
ing of the endomyocardial biopsies.
Dr Karamichalis. The data concerning the short follow-up of
those 5 patients corresponds to the time after retransplantation.
All patients that had their first transplant and made it to retrans-
plantation had surveillance angiograms at the first anniversary of
their transplant and subsequently every other year. If there was ev-
idence of CAV, then they would receive more frequent surveillance
for CAV and treatments.
At the time of catheterization, all patients also had endomyocar-
dial biopsies. So given the median graft survival of both the infant
and the older group, the older being 3.9 years, then all of those pa-
tients should have at least had 2 or 3 endomyocardial biopsies and
at least 3 angiograms.
Dr Chen. Do you know if it’s the practice to treat episodes of
transplant coronary disease in the absence of rejection? So could
it be that the coronary disease was detected in the infants and
they were treated before there was biopsy-proven rejection and
thus the lower incidence of rejection?
Dr Karamichalis. Once CAV is diagnosed in these patients at
our center, they get treated. And the strategy that we use, includes
statins or antilipid agents, we also use MMF and rapamycin, an
antiproliferative agent, to decelerate the progression of CAV in
these patients. So any evidence or any signs of CAV, no matter
how severe or mild they might be, they get treated. The treatment
escalates based on the severity of the CAV.
Dr Chen. Finally, is it possible that the decreased graft survival
and increased rejection in your group 2 was related to medication
noncompliance, given that the fact that the average age of this
group was 9, plus or minus 6 years, at their primary transplant,
which would render many of them medically recalcitrant adoles-
cents at the time of their initial post-transplant years.
Dr Karamichalis. I think that’s an excellent point and it’s defi-
nitely something worth mentioning. In the older population, there
may be a compliance issue of which we are not aware. Even though
we discussed it, we haven’t really searched specifically for noncom-
pliance in these patients, but it’s definitely something that is well
known to cause rejection inpatientswhodon’t take theirmedications.
Dr Chen. Thanks. These are very provocative and very interest-
ing data. I’m very interested in how these findings play out as you
follow these patients postretransplant.
Dr Carl Backer (Chicago, Ill). John, congratulations on a very
nice analysis. Clearly, this is a huge amount of work.
I have a question. Given the data that you have on retransplanta-
tion, I’d like to ask your opinion about 2 high-risk groups. The first
is the patient who has had their first transplant, doesn’t come off by-
pass because they have right ventricular dysfunction, and now
you’re contemplating whether or not you should relist them for an-
other transplant. Did you have any patients like that in your series
and what are your thoughts about that population group?
Dr Karamichalis. Thank you for your comments and your
question.rdiovascular Surgery c Volume 141, Number 1 229
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XNo,wedid not have any relisting of early graft failure.One patient
retransplantedwasmore than a year after his primary transplant. Ev-
erybody else got retransplanted at 2 ormore years after their primary
transplant. So I do not believewe have anybody that was relisted fol-
lowing primary transplantation with failure to come off bypass.
Dr Backer. The second question is: What do you think about
a third-time transplant? Do you have any patients who you’ve
transplanted a third time and what’s your opinion about that?230 The Journal of Thoracic and Cardiovascular SurgDr Karamichalis. I’m aware of 1 patient who was offered
third-time retransplantation. That patient refused to be relisted
and died subsequently of PTLD, which was unrelated to CAV or
rejection. I know other centers have reported third-time retrans-
plantations. I guess it would be a collective decision between ev-
erybody involved. And, if somebody makes a compelling case,
then a third transplant should be offered but it would only be on
a case-to-case basis.ery c January 2011
